MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-10-2026
Apyx Medical Corporation EBITDA 2011-2026 | APYX
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA Apyx Medical Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -5.79 M | -18.2 M | -16.6 M | -22.7 M | -13.5 M | -19.2 M | -20.1 M | -12.2 M | -3.04 M | -3.06 M | -6.17 M | -4.97 M | -1.2 M | 1.9 M | 157 K |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.9 M | -22.7 M | -9.65 M |
Quarterly EBITDA Apyx Medical Corporation
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | -2.91 M | - | - | - | -6.46 M | - | - | - | -5.41 M | - | -5.09 M | -5.5 M | -5.65 M | - | -3.29 M | -3.6 M | -4.52 M | - | -3.71 M | -5.73 M | -7.28 M | - | -4.25 M | -4.11 M | -5.54 M | - | -2.73 M | -2.76 M | -2.52 M | - | -2.66 M | -1.13 M | -1.56 M | - | -44 K | -337 K | -1.81 M | - | -1.18 M | -1.13 M | -2.06 M | - | -1.71 M | -1.29 M | 290 K | - | 145 K | -1.23 M | -453 K | - | 922 K | 680 K | 620 K | - | 925 K | 1 M | 814 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1 M | -7.28 M | -2.37 M |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Medical devices industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
GenMark Diagnostics, Inc.
GNMK
|
-3.98 M | - | - | $ 1.77 B |  USA |
 |
Acutus Medical
AFIB
|
-11.5 M | - | -26.83 % | $ 2.62 M | USA |
 |
AdaptHealth Corp.
AHCO
|
473 M | $ 12.03 | -0.33 % | $ 1.63 B | USA |
 |
Allied Healthcare Products
AHPI
|
-815 K | - | 3.58 % | $ 2.21 M | USA |
 |
ClearPoint Neuro
CLPT
|
-23.4 M | $ 9.06 | -3.41 % | $ 257 M | USA |
 |
Obalon Therapeutics, Inc.
OBLN
|
-9.8 M | - | -5.86 % | $ 30.6 M | USA |
 |
Bruker Corporation
BRKR
|
437 M | $ 36.22 | -1.42 % | $ 5.4 K | USA |
 |
Apollo Endosurgery
APEN
|
-30.2 M | - | - | $ 475 M | USA |
 |
OrthoPediatrics Corp.
KIDS
|
-18.1 M | $ 15.68 | -1.63 % | $ 368 M | USA |
 |
CryoLife, Inc.
CRY
|
23.2 M | - | -4.14 % | $ 702 M | USA |
 |
Avinger
AVGR
|
-16.3 M | - | -20.74 % | $ 369 K | USA |
 |
Align Technology
ALGN
|
753 M | $ 166.59 | -3.07 % | $ 12.5 B | USA |
 |
AxoGen
AXGN
|
-1.19 M | $ 30.87 | -5.44 % | $ 1.42 B | USA |
 |
Axonics Modulation Technologies
AXNX
|
-53.2 M | - | - | $ 3.31 B | USA |
 |
Aziyo Biologics
AZYO
|
-24.1 M | - | 1.37 % | $ 20.5 M | USA |
 |
Soliton, Inc.
SOLY
|
-14.1 M | - | -1.42 % | $ 435 M | USA |
 |
EDAP TMS S.A.
EDAP
|
-17.9 M | $ 3.44 | -2.0 % | $ 129 M |  France |
 |
Hancock Jaffe Laboratories, Inc.
HJLI
|
88.4 K | - | -1.98 % | $ 98.3 M | USA |
 |
Itamar Medical Ltd.
ITMR
|
-8.53 M | - | 0.03 % | $ 1.58 B |  Israel |
 |
Misonix, Inc.
MSON
|
-15.9 M | - | - | $ 462 M | USA |
 |
Neovasc
NVCN
|
-31.1 M | - | - | $ 111 M |  Canada |
 |
Butterfly Network
BFLY
|
-65.5 M | $ 4.01 | -3.14 % | $ 849 M | USA |
 |
Smith & Nephew plc
SNN
|
1.16 B | $ 31.7 | -2.85 % | $ 23.8 B |  Britain |
 |
Intersect ENT, Inc.
XENT
|
-64.8 M | - | - | $ 955 M | USA |
 |
Cytosorbents Corporation
CTSO
|
-13.5 M | $ 0.58 | -1.69 % | $ 36.1 M | USA |
 |
TELA Bio
TELA
|
-33.1 M | $ 0.67 | 5.89 % | $ 31.5 M | USA |
 |
BIOLASE
BIOL
|
-15.1 M | - | -13.19 % | $ 166 K | USA |
 |
Delcath Systems
DCTH
|
898 K | $ 9.63 | -0.72 % | $ 345 M | USA |
 |
BioSig Technologies
BSGM
|
-67.6 M | - | 37.08 % | $ 85.7 M | USA |
 |
Boston Scientific Corporation
BSX
|
4.98 B | $ 61.38 | -1.92 % | $ 90.9 B | USA |
 |
Alphatec Holdings
ATEC
|
-4.64 M | $ 11.14 | 1.55 % | $ 1.67 B | USA |
 |
CONMED Corporation
CNMD
|
120 M | $ 34.09 | 0.07 % | $ 1.06 B | USA |
 |
FONAR Corporation
FONR
|
9.84 M | $ 18.6 | - | $ 122 M | USA |
 |
Edwards Lifesciences Corporation
EW
|
1.42 B | $ 80.75 | -0.49 % | $ 47.2 B | USA |
 |
Globus Medical
GMED
|
757 M | $ 90.0 | 1.55 % | $ 12.2 B | USA |
 |
Helius Medical Technologies
HSDT
|
-12.4 M | $ 1.74 | -8.38 % | $ 1.06 M | USA |
 |
Integra LifeSciences Holdings Corporation
IART
|
70.8 M | $ 9.32 | 0.11 % | $ 718 M | USA |
 |
Inspire Medical Systems
INSP
|
64.9 M | $ 54.12 | -0.01 % | $ 1.59 B | USA |
 |
Conformis
CFMS
|
-42.2 M | - | - | $ 16.4 M | USA |
 |
IRIDEX Corporation
IRIX
|
-2.05 M | $ 1.0 | 0.34 % | $ 16.9 M | USA |
 |
Integer Holdings Corporation
ITGR
|
352 M | $ 85.59 | -0.04 % | $ 2.97 B | USA |
 |
LENSAR
LNSR
|
-21 M | $ 5.85 | -0.68 % | $ 70 M | USA |
 |
Cardiovascular Systems
CSII
|
-32.1 M | - | 0.15 % | $ 844 M | USA |
 |
Cutera
CUTR
|
-148 M | - | -10.19 % | $ 1.99 M | USA |
 |
Medtronic PLC
MDT
|
8.82 B | $ 86.29 | - | $ 111 B | USA |
 |
Dynatronics Corporation
DYNT
|
-1.97 M | - | 14.99 % | $ 929 K | USA |
 |
Eargo
EAR
|
-106 M | - | - | $ 10.2 M | USA |
 |
Myomo
MYO
|
-13.5 M | $ 0.66 | -5.67 % | $ 27.6 M | USA |